title: Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.
authors.affiliation: InnovaTID Pharmaceuticals Inc, Cambridge, Massachusetts.
authors.forename: Xiao
authors.initials: X
authors.lastname: Tong
authors.affiliation: InnovaTID Pharmaceuticals Inc, Cambridge, Massachusetts.
authors.forename: Ann D
authors.initials: AD
authors.lastname: Kwong
mesh_terms: D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D011810:Quinoxalines; D012254:Ribavirin; D007372:Interferons
keywords: MK-5172; hepatitis C virus; resistance; sofosbuvir